Program
Lisinopril
Also written as “LP-003 Injection”, “lisinopril” and “LP-005 Injection”.
Its studies are mostly in Hypertension · Chronic Urticaria · Hemoglobinuria, Paroxysmal · Fasting · Rhinitis, Allergic, Seasonal, led by 10 companies.
Drug pageLisinopril: every studyMany companies study it; this page follows only the 39 they lead. All 79 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Longbio Pharmaits history only | 149 open or running | phase 3since Dec 5, 2025 | Jun 27, 2023 | Nov 2026phase 1 · NCT06604949 |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Apr 13, 2005 | Apr 13, 2005 | none ahead |
| Novartisits history only | 60 open or running | phase 4since Sep 12, 2005 | Sep 10, 2005 | none ahead |
| IPCA Laboratoriesits history only | 40 open or running | phase 1since Nov 5, 2012 | Nov 5, 2012 | none ahead |
| Longbio Pharma (Suzhou)its history only | 33 open or running | phase 2since Apr 23, 2026 | Apr 23, 2026 | Jul 16, 2027phase 2 · NCT07816432 |
| Par Healthits history only | 20 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Jan 2, 2018 | Jan 2, 2018 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Sep 1, 2013 | Sep 1, 2013 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Sep 20, 2021 | Sep 20, 2021 | none ahead |
Also a collaborator on its studies: PharmaKinetics Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pharmtechnology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2021First study: phase 1 study in BioequivalenceFirst studyNCT05061901 · 38 enrolled · Russian Federation
TargetBeta
“An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity”NCIt, by rule
“Angiotensin-converting enzyme inhibitor”ChEMBL 37, by rule
Studies
The one study Pharmtechnology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05061901Bioequivalence · Russian Federation | 1 | Completed | Nov 6, 2021 | 38 |
How it is read
Names in the registry
- “Lisinopril”, 10 entries
- “LP-003 Injection”, 5 entries
- “lisinopril”, 5 entries
- “LP-005 Injection”, 4 entries
- “LP-003”, 2 entries
Codes read as this program: LP003, LP005, LP001.
Conditions, from the studies’ own filings
- Hypertension, 12 studies
- Chronic Urticaria, 4 studies
- Hemoglobinuria, Paroxysmal, 3 studies
- Fasting, 3 studies
- Rhinitis, Allergic, Seasonal, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.